{"id":652280,"date":"2023-05-22T09:30:01","date_gmt":"2023-05-22T09:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=652280"},"modified":"2023-05-22T09:30:01","modified_gmt":"2023-05-22T09:30:01","slug":"phosphoglucomutase-pgm-1-deficiency-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-companies-orpha-labs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/phosphoglucomutase-pgm-1-deficiency-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-companies-orpha-labs_652280.html","title":{"rendered":"Phosphoglucomutase (PGM 1) Deficiency Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)| Companies &#8211; Orpha Labs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Phosphoglucomutase (PGM 1) Deficiency Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)| Companies - Orpha Labs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Phosphoglucomutase (PGM 1) Deficiency Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)| Companies - Orpha Labs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Phosphoglucomutase 1 Deficiency Market Insights, Epidemiology, and Market Forecast-2032&#8221; report deliver an in-depth understanding of the Phosphoglucomutase 1 Deficiency, historical and forecasted epidemiology as well as the Phosphoglucomutase 1 Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;<strong>&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/phosphoglucomutase-pgm-1-deficiency-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Phosphoglucomutase 1 Deficiency Market Insights, Epidemiology, and Market Forecast-2032<\/a>&#8220;&#8221;<\/strong>&nbsp;report delivers an in-depth understanding of the Phosphoglucomutase, epidemiology insights, Phosphoglucomutase market trends, therapies, and key companies working in the Phosphoglucomutase Market in the 7MM.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Phosphoglucomutase (PGM 1) Deficiency Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A rare genetic condition called phosphoglucomutase 1 deficiency affects protein glycosylation, glycolysis, and glycogen metabolism. Formerly classified as GSD XIV, it was recently reclassified as PGM1-CDG, a congenital disorder of glycosylation. PGM1-CDG typically presents as a multisystem illness.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/c8c09504fa221cacd744c51bd64e519c.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/phosphoglucomutase-pgm-1-deficiency-market\">Phosphoglucomutase (PGM 1) Deficiency Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Phosphoglucomutase (PGM 1) Deficiency Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phosphoglucomutase (PGM 1) Deficiency treatment cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phosphoglucomutase (PGM 1) Deficiency diagnosed cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phosphoglucomutase (PGM 1) Deficiency incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phosphoglucomutase (PGM 1) Deficiency prevalent cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phosphoglucomutase (PGM 1) Deficiency Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Phosphoglucomutase 1 Deficiency market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Phosphoglucomutase 1 Deficiency market trends by analyzing the impact of current Phosphoglucomutase 1 Deficiency therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Phosphoglucomutase 1 Deficiency market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Phosphoglucomutase 1 Deficiency market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Phosphoglucomutase 1 Deficiency market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies Working in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/phosphoglucomutase-pgm-1-deficiency-market\">Phosphoglucomutase (PGM 1) Deficiency Market<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Orpha Labs<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phosphoglucomutase (PGM 1) Deficiency Therapies Covered and Analyzed in the Report:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">ORL-1G &#8211; D-galactose<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the Key Companies and Emerging Therapies in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/phosphoglucomutase-pgm-1-deficiency-market\">Phosphoglucomutase (PGM 1) Deficiency Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&nbsp;Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phosphoglucomutase (PGM 1) Deficiency&nbsp; Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Phosphoglucomutase (PGM 1) Deficiency&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phosphoglucomutase (PGM 1) Deficiency Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phosphoglucomutase (PGM 1) Deficiency Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/phosphoglucomutase-pgm-1-deficiency-market\">Phosphoglucomutase (PGM 1) Deficiency Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=phosphoglucomutase-pgm-1-deficiency-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-companies-orpha-labs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=phosphoglucomutase-pgm-1-deficiency-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-companies-orpha-labs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Phosphoglucomutase 1 Deficiency Market Insights, Epidemiology, and Market Forecast-2032&#8221; report deliver an in-depth understanding of the Phosphoglucomutase 1 Deficiency, historical and forecasted epidemiology as well as the Phosphoglucomutase 1 Deficiency market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/phosphoglucomutase-pgm-1-deficiency-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-companies-orpha-labs_652280.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-652280","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/652280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=652280"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/652280\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=652280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=652280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=652280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}